Solid Biosciences is trading 6.69% up at $8.93 in pre-market, with no clear company-specific announcement identified for September 16, 2026. - Recent coverage focused on the September 14 investor conference and an upcoming fourth-quarter FDA meeting for SGT-003. - The move may reflect speculative biotechnology trading or a rebound after several declining sessions. - The latest investor-relations release located was dated September 2.